Gain Therapeutics (GANX) Has a New Rating from Oppenheimer

By Carrie Williams

In a report released today, Hartaj Singh from Oppenheimer initiated coverage with a Buy rating on Gain Therapeutics (GANXResearch Report) and a price target of $30.00. The company’s shares closed last Friday at $13.98.

According to, Singh is a 4-star analyst with an average return of 14.7% and a 46.9% success rate. Singh covers the Healthcare sector, focusing on stocks such as Opthea Limited Sponsored ADR, Catabasis Pharmaceuticals, and Vertex Pharmaceuticals.

Currently, the analyst consensus on Gain Therapeutics is a Moderate Buy with an average price target of $22.00, implying a 52.6% upside from current levels. In a report released today, BTIG also initiated coverage with a Buy rating on the stock with a $30.00 price target.

See today’s analyst top recommended stocks >>

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Gain Therapeutics Inc is a development-stage biotechnology company developing novel therapeutics to treat diseases caused by protein misfolding, with an initial focus on lysosomal storage disorders (LSDs), including rare genetic diseases and neurological disorders. Its pipeline includes the GLB1 gene, GBA1 gene, IDUA gene, and GALC gene.